Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 4634817

Drug Profile

PF 4634817

Alternative Names: PF-04634817; PF-46334817; PF4634817

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic macular oedema; Diabetic nephropathies; Hepatic fibrosis

Most Recent Events

  • 08 Oct 2015 Pfizer terminates a phase II trial in Diabetic macular oedema in USA, Bulgaria, Czech Republic, Hungary, Germany, Israel, Poland, Romania and Moldova (NCT01994291; EudraCT2013-003147-27)
  • 10 Sep 2014 Phase-II clinical trials in Diabetic macular oedema in Moldova (PO)
  • 01 Sep 2014 Pfizer completes a phase II trial in Diabetic nephropathies in Argentina, Australia, Canada, Germany, Hong Kong, Italy, Malaysia, Peru, Poland, Puerto Rico, Romania, South Korea, Spain and USA (NCT01712061; EudraCT2012-003332-23)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top